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Abstract
Background—The impact of abnormal spirometric findings on risk for incident heart failure
among older adults without clinically apparent lung disease is not well elucidated.
Methods—We evaluated the association of baseline lung function with incident heart failure,
defined as first hospitalization for heart failure, in 2125 participants of the community-based
Health, Aging, and Body Composition Study (age, 73.6±2.9 years; 50.5% men; 62.3% white;
37.7% black) without prevalent lung disease or heart failure. Abnormal lung function was defined
either as forced vital capacity (FVC) or forced expiratory volume in 1st second (FEV1) to FVC
ratio below lower limit of normal. Percent predicted FVC and FEV1 were also assessed as
continuous variables.
Results—During follow-up (median, 9.4years), heart failure developed in 68 of 350 (19.4%)
participants with abnormal baseline lung function, as compared to 172 of 1775 (9.7%) participants
with normal lung function (hazard ratio [HR], 2.31; 95% confidence interval [CI], 1.74-3.07; P<.
001). This increased risk persisted after adjusting for previously identified heart failure risk factors
in the Health ABC Study, body mass index, incident coronary heart disease, and inflammatory
markers (HR, 1.83; 95% CI, 1.33-2.50; P<.001). Percent predicted (%) FVC and FEV1 had a
linear association with heart failure risk (HR, 1.21; 95%CI, 1.11-1.32 and 1.18; 95%CI, 1.10-1.26,
per 10% lower %FVC and %FEV1, respectively; both P<.001 in fully adjusted models). Findings
were consistent in sex and race subgroups, and for heart failure with preserved or reduced ejection
fraction.
Conclusions—Abnormal spirometric findings in older adults without clinical lung disease are
associated with increased heart failure risk.
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Impaired lung function, as evaluated with spirometry, is encountered in more than 10% of
the general population1; interestingly, 40% to 88% of patients do not have a prior diagnosis
of lung disease.1 In retrospective studies from administrative data,2-5 COPD has been
associated with risk for cardiovascular disease and heart failure. Also, %FVC has been
proposed as a cardiovascular risk factor,6 and %FEV1 has been associated with all-cause and
cardiovascular mortality.7, 8 The cardiovascular risk associated with COPD has been
partially attributed to systemic inflammation.9 However, in a large cohort study,6 the
increased risk in men with impaired lung function could not be entirely explained by the
concomitant increase in serum inflammatory markers.
Spirometric parameters have been included in studies investigating predictors of heart
failure.10, 11 However, no data exist on the impact of lung function on heart failure risk in
the elderly, especially in the absence of clinically apparent lung disease. The association of
lung function with heart failure risk in this population segment might be important,
considering that the elderly represent a rapidly growing segment and have the highest
prevalence of both abnormal lung function1 and heart failure.12 While use of spirometry as a
screening tool for early diagnosis of lung disease is still a subject of debate,13, 14 whether
detection of lung function abnormalities has the potential to identify elderly at risk for heart
failure is unknown.
In the Health ABC Study, a community-based cohort study of well-functioning older adults,
a substantial proportion had abnormal spirometric findings at baseline without clinically
diagnosed lung disease.15 Using 10-year follow-up data, we investigated the association
between lung function and risk for incident heart failure in participants without clinical lung
disease or heart failure at baseline, explored for interaction effects of sex and race, and
assessed the role of inflammation and incident coronary events.
Methods
Study Population
Health ABC is a community-based study of 3075 well-functioning men and women aged 70
to 79 years at inception. Participants were recruited in 1997-98 from a random sample of
white Medicare beneficiaries and all age-eligible black residents in designated zip code
areas surrounding Pittsburgh and Memphis. To be eligible, participants had to report no
difficulty in walking 1/4 mile or climbing 10 stairs. Exclusion criteria included difficulties
with daily activities, cognitive impairment, inability to communicate, intention of moving
within 3 years, or participation in a trial involving lifestyle interventions. The institutional
review boards at both sites approved the study.
For this analysis, we excluded participants with (1) history of heart failure or inconclusive or
missing data on heart failure at baseline (n=140); (2) history of lung disease or inconclusive
or missing data on lung disease at baseline (n=343); (3) contraindications to spirometry
(n=165) or poor quality spirometric data (n=302). Lung disease was considered present
when both a history of asthma or COPD and use of pulmonary medications and/or oral
steroids were reported. History alone or medications alone was considered inconclusive
evidence. The current analysis included 2125 participants (Figure 1).
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Risk Factor Definitions
Cardiovascular disease status (including heart failure) at baseline was based on ICD 9-CM
codes as reported by Medicare Services for the years 1995-1998; self-reported history; and
medications. History of coronary revascularization, electrocardiographic evidence of
myocardial infarction, or history of myocardial infarction or angina accompanied by use of
antianginal medications was considered evidence of coronary heart disease. Diabetes was
defined as history of diabetes or use of antidiabetic medications. Hypertension was defined
as use of antihypertensive medications and self-reported history or physician diagnosis of
hypertension. Smoking was classified as current, past (if ≥100 lifetime cigarettes), or never.
Left ventricular hypertrophy was determined from electrocardiography.16 Incident coronary
heart disease was defined as (1) hospitalization for adjudicated myocardial infarction or
angina, or (2) coronary revascularization.
Pulmonary Function
Spirometry was performed with a horizontal dry rolling seal spirometer (SensorMedics
Corporation, Yorba Linda, CA).15 Contraindications were recent abdominal, thoracic, or
ophthalmological surgery, recent myocardial infarction, or other recent cardiac illness. A 4-
point scoring system was used to grade quality for FVC and FEV1 curves; a score of 2-4
indicates that the American Thoracic Society quality criteria for acceptability and
reproducibility were met.17 This analysis includes only FVC and FEV1 values with quality
score of 2 or higher.
Abnormal spirometric parameters were defined according to age-, sex-, and race-specific
normalized reference values of NHANES III and predicted values for FVC and FEV1 were
calculated from the NHANES III equations.18 Abnormal lung function was defined as
%FVC or FEV1/FVC below the lower limit of normal (5th percentile), and further classified
into obstructive (when FEV1/FVC was below lower limit of normal) and restrictive (when
FEV1/FVC was above and %FVC was below lower limit of normal).19
Inflammatory Markers
Interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α), C-reactive protein (CRP) were
available in 1906 of 2125 (89.7%) participants and were measured in duplicate by ELISA in
the Core Laboratory at the University of Vermont.20
Outcome
Participants were asked to report all hospitalizations and every 6 months they were
contacted to elicit information about interim events. All first admissions with an overnight
stay confirmed to be related to heart failure by independent adjudication were classified as
incident heart failure. Briefly, heart failure was confirmed if, in addition to physician
diagnosis of heart failure, there was documentation of (1) symptoms (e.g. shortness of
breath, orthopnea) and signs (e.g. edema, pulmonary crackles); (2) supporting imaging
findings (e.g. pulmonary oedema on chest radiography); or (3) medical therapy for heart
failure, including at least a diuretic and a vasodilator and/or digitalis. Left ventricular
ejection fraction (LVEF) at heart failure diagnosis was not prospectively evaluated. Thus,
information on LVEF was based on echocardiography or left ventriculography reports at
time of heart failure diagnosis; LVEF data were available in 187 of 240 (77.9%) participants
with incident heart failure.
Statistical Analysis
The association of abnormal lung function (treated as a binary variable) and continuous
spirometric parameters with heart failure risk was assessed with proportional hazards
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models. Possible interaction of lung function and spirometric variables with sex and race
was evaluated using appropriate interaction terms. The functional form (i.e. linear vs. non-
linear) of continuous variables was explored with fractional polynomials.21 The
proportionality of hazards was assessed with the Schoenfeld residuals and smoothed hazard
plots.
In multivariate proportional hazards models, we controlled for body mass index (BMI),
which has been shown to be associated with lung function,22 previously identified
predictors of heart failure in Health ABC (age, history of coronary heart disease, smoking,
systolic blood pressure, heart rate, creatinine, fasting glucose, albumin, and
electrocardiographic left ventricular hypertrophy),16 and incident coronary heart disease as
a time-varying covariate. Finally, we controlled for inflammatory markers in the subset of
participants (n=1906 of 2125; 89.7%) with available data. In secondary analyses, we
assessed (1) the impact of obstructive versus restrictive pattern on heart failure risk and (2)
the association of lung function and spirometric parameters with risk for heart failure with
reduced versus preserved LVEF, using a cut-off point of 40%.
Complete data on covariates were available in 2072 of 2125 (97.5%) participants in the main
analysis cohort and in 1869 of 1906 (98.1%) in the subset with inflammatory markers
available. Thus, we repeated multivariable analyses in five datasets imputed with chained
equations23 and obtained estimates by combining the imputed datasets.24 Both the outcome
and time to event were included in the equations (in addition to the covariates) for
calculation of missing values. Analyses were performed with STATA 10 (StataCorp,
College Station, TX). A two-sided P<.05 value was considered significant.
Results
Participant Characteristics and Outcomes
The participant characteristics according to baseline lung function are shown in Table 1.
After a median follow-up of 9.4 years (interquartile range, 7.4-9.4 years), heart failure
developed in 240 (11.3%) participants (14.1 per 1000 person-years; 95% CI, 12.4-16.0).
Baseline Lung Function and Incident Heart Failure
Among the 1775 participants with normal lung function, heart failure developed in 172
(9.7%) participants (11.8 per 1000 person-years). In comparison, among the 350 participants
with abnormal lung function, heart failure developed in 68 (19.4%) participants (27.1 per
1000 person-years). In models controlling for BMI, predictors of heart failure in the Health
ABC Study,16 and incident coronary heart disease, participants with abnormal lung function
were still at higher risk (Table 2). In the subset of participants with available inflammatory
markers (1906 of 2125; 89.7%), addition of IL-6, TNF-α, and CRP did not attenuate this
association (Table 2). The proportional hazards assumption was valid in all models. Figure 2
shows the annualized heart failure risk according to lung function. The increased heart
failure risk persisted over time without attenuation. The estimates were not altered in
analyses performed in five imputed datasets (data not shown).
The increased heart failure risk associated with abnormal lung function was more
pronounced in women compared to men and in white compared to black participants in
adjusted models (Figure 3); however, this differential association did not reach statistical
significance (P=.32 and P=.24 for the interaction terms for sex and race, respectively).
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Obstructive vs. Restrictive Baseline Pattern and Incident Heart Failure
Compared to participants with normal lung function at baseline, those with obstructive
pattern (n=163) had HR 1.44 (95% CI, 0.92-2.26; P=.11) and those with restrictive pattern
(n=187) had HR 2.12 (95% CI, 1.50-3.01; P<.001) for incident heart failure in models
adjusted for predictors of heart failure and BMI (P=.15 for the comparison of patterns).
Continuous Spirometric Parameters and Incident Heart Failure
Both %FVC and %FEV1 were associated with heart failure risk in unadjusted analyses
(Table 3, Figure 4) and in models controlling for predictors of heart failure, BMI, and
incident coronary heart disease (Table 3); FEV1/FVC ratio was marginally significant. The
strength of association was comparable for %FVC and %FEV1. These associations persisted
when IL-6, TNF-α, and CRP were added in the model (HR, 1.21; 95% CI, 1.11-1.32; P<.
001; and HR, 1.18; 95% CI, 1.09-1.26; P<.001, per 10% lower %FVC and %FEV1,
respectively). There was no evidence of non-linear association of %FVC or %FEV1 with
risk. Hazards were proportional in all models. The estimates were not altered in analyses
done in five imputed datasets (data not shown).
Results were similar for sex- and race-specific analyses (Table 3). The interaction effects of
sex and race on spirometric parameters were nonsignificant in fully adjusted models (P=.82
and P=.74 for the effect of sex and P=.42 and P=.50 for the effect of race on %FVC and
%FEV1, respectively).
Among participants with normal lung function (n=1775), both %FVC and %FEV1 were still
associated with heart failure risk in models adjusted for predictors of heart failure and BMI
(HR, 1.14; 95% CI, 1.02-1.29; P=.02, and 1.12; 95% CI, 1.01-1.23; P=.03, per 10% lower
%FVC and %FEV1, respectively).
Heart Failure with Reduced vs. Preserved Ejection Fraction
Data on post-heart failure LVEF were available in 187 of 240 (77.9%) participants with
incident heart failure. Mean LVEF in these participants was 41±16%; 96 of 187 (51.3%) had
LVEF ≤40% and 91 of 187 (48.7%) had LVEF >40% at heart failure diagnosis. Abnormal
lung function was associated with higher risk for heart failure with preserved and reduced
LVEF in models adjusted for BMI, predictors for heart failure, incident coronary heart
disease and inflammatory markers (Table 2). Finally, % FVC and %FEV1 were significantly
associated with risk for heart failure with reduced and preserved ejection fraction in
unadjusted and adjusted models (Table 3).
Discussion
In this study, we observed increased heart failure incidence among older persons with lung
function alterations but without clinically apparent lung disease. This increased heart failure
risk persisted after controlling for multiple heart failure risk factors, incident coronary heart
disease, and inflammatory markers, and did not attenuate over time. When analysed as
continuous variables, both FVC and FEV1 had a linear association with heart failure risk in
adjusted models. These findings were consistent in sex and race subgroups.
Several mechanisms might contribute to development of heart failure in older persons with
abnormal lung function in the absence of established lung disease. First, low-grade systemic
inflammation is present both in patients with chronic lung diseases25 and in patients with
abnormal lung volumes without established lung disease6; notably, the latter is also
supported by our findings. Inflammation may lead to heart failure through direct myocardial
damage26 and accelerated atherosclerosis,27 and inflammatory pathways have been
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associated with heart failure risk in epidemiologic studies.28 Second, impaired lung function
is characterized by oxidative stress,29 which has been shown to directly affect myocardial
function.30, 31 Finally, changes in respiratory mechanics and intrathoracic pressure can
reduce cardiac output by affecting preload and afterload.32, 33 Because mechanisms like
inflammation and oxidative stress are also associated with coronary heart disease,34 it is
possible that heart failure risk is primarily mediated through incident coronary heart disease.
However, controlling for inflammatory markers and incident coronary heart disease did not
alter the associations with heart failure risk in our study, suggesting a more direct cardio-
pulmonary interaction. Notably, in a recent report,35 percentage emphysema and FEV1/FVC
were associated with left ventricular filling. Interestingly, in concordance with the impaired
ventricular filling hypothesis, in our study the association of impaired lung function with
heart failure risk was stronger for heart failure with preserved LVEF; however, post-heart
failure LVEF was not prospectively evaluated in Health ABC and thus these findings should
be interpreted with caution.
In our analyses, restrictive pattern of abnormal lung function demonstrated a trend towards
stronger association with heart failure risk than obstructive pattern. Considering that fewer
participants had obstructive as compared to restrictive spirometry pattern, the lack of
statistical significance in the former group might represent lack of power. Although both
spirometric patterns are encountered among heart failure patients,36 restrictive spirometric
pattern is more common37; notably, this pattern is met in 10-12% of older persons.38 One
may therefore contend that undiagnosed heart failure or asymptomatic left ventricular
dysfunction at baseline is primarily driving our findings. However, we found that the
excessive risk for heart failure associated with abnormal baseline lung function was constant
over time. Because it is unlikely that heart failure will remain undiagnosed for many years, it
is improbable that the observed association can be entirely ascribed to undetected heart
failure.
What are the practical implications of these findings? Considering the association of %FEV1
and %FVC with heart failure risk, it is possible that spirometry might be used to predict
heart failure risk in the elderly. Indeed, the Framingham investigators suggested that FVC
can be used to predict heart failure risk11, and use of %FEV1 has been proposed as a marker
with broad clinical utility in risk assessment and possible prevention of both respiratory
(COPD and lung cancer) and cardiovascular diseases.39 Whether spirometry is a cost-
effective tool for screening purposes in the elderly needs further study. However, whenever
abnormal spirometric findings are encountered in elderly patients, a comprehensive
assessment for heart failure risk may be warranted.16
Our study has several limitations. Echocardiography was not performed at baseline and
therefore participants with asymptomatic structural cardiac abnormalities may have been
included in our study. Diagnosis of heart failure was based on hospitalization and thus
absolute heart failure incidence is likely underestimated. Hospitalization rates for heart
failure may be selectively higher among participants with impaired lung function because of
reduced capacity to compensate heart failure, leading to more severe presentation.
Participants with undiagnosed lung disease at baseline may have been included in the
analyses. Specific data on left- versus right-sided heart failure were not available. However,
isolated right ventricular failure is far less common than left ventricular failure even among
patients with established COPD.40 Finally, Health ABC included only older adults of white
or black race; therefore, these findings may not apply to younger adults or other races.
In conclusion, we observed a significant association between abnormal spirometric findings
and heart failure risk among older persons. These findings were consistent in sex- and race-
based subgroups and persisted after controlling for incident coronary heart disease and
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inflammatory markers. The practical implication of our findings, including the possible
clinical use of spirometry to detect individuals at increased risk for heart failure, needs
further study.
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Figure 1.
Flowchart of participant selection for the current analysis.
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Figure 2.
Annualized risk of incident heart failure for participants with normal versus abnormal lung
function tests at baseline, adjusted for predictors of heart failure and body mass index.
Smoothed hazard estimate was obtained using an Epanechnikov kernel. Although the
absolute annualized risk increases from year 1 to year 5 before reaching a plateau in both
groups, the relative risk remains stable over time.
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Figure 3.
Kaplan-Meier rates of incident heart failure by baseline lung function status in sex and race
subgroups, adjusted for predictors of heart failure and body mass index.
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Figure 4.
Unadjusted incident heart failure rates according to baseline forced expiratory volume in 1st
sec (FEV1) and forced vital capacity (FVC) values. Rates are expressed in cases per 1000
person-years.
Georgiopoulou et al. Page 13
Am J Med. Author manuscript; available in PMC 2012 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Georgiopoulou et al. Page 14
Table 1
Baseline participant characteristics
Characteristic Normal Spirometric Findings(n=1775)
Abnormal Spirometric Findings
(n=350) P value
Age, years 73.6±2.9 73.2±3.0 .006
Males, % 47.6 65.7 <.001
Whites, % 61.8 65.1 .25
Smoking status
 Current, % 7.8 17.4
<.001
 Past, % 44.2 52.6
Body mass index, kg/m2 27.3±4.6 26.8±4.8 .08
Systolic blood pressure, mmHg 136±20 137±20 .18
Diastolic blood pressure, mmHg 71±11 72±11 .28
Heart rate, beats/minute 64±10 67±12 .001
Fasting glucose, mg/dl 103±32 107±34 .003
Serum creatinine, g/dl 1.04±0.36 1.09±0.42 .06
Serum albumin, mg/dl 4.00±0.31 3.98±0.31 .19
Hypertension, % 50.6 60.0 .002
Diabetes mellitus, % 16.9 13.1 .06
Coronary heart disease, % 16.0 19.6 .10
Left ventricular hypertrophy, % 10.7 11.7 .57
Inflammatory markers
 Interleukin-6, pg/ml* 1.68 (1.16, 2.51) 2.20 (1.50, 1.36) <.001
 Tumour necrosis factor α, pg/ml* 3.11 (2.40, 4.05) 3.20 (2.51, 4.01) .21
 C-reactive protein, μg/ml* 1.56 (0.95, 2.84) 1.81 (1.12, 3.53) <.001
Spirometric parameters
 FEV1, % predicted 102±16 69±14 -
 FVC, % predicted 99±14 76±16 -
 FEV1 to FVC ratio 77±5 68±10 -
FEV1=Forced Expiratory Volume in 1st second; FVC=Forced Vital Capacity
P values were derived with the Mann-Whitney test for continuous variables and the Fisher exact test for categorical variables.
*
Baseline serum concentrations of interleukin-6, tumour necrosis factor α, and C-reactive protein were available in 2020 (95.1%), 1996 (93.9%),
and 2104 (99.0%) of 2125 participants, respectively; values are expressed as median (interquartile range) because of highly skewed distributions.
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Table 3
Baseline spirometric parameters and risk for heart failure
Unadjusted Adjusted*
HR† (95% CI) P HR† (95% CI) P
Total study population (n=2125)
% predicted FEV1 1.26 (1.18-1.34) <.001 1.20 (1.12-1.28) <.001
% predicted FVC 1.33 (1.23-1.44) <.001 1.24 (1.14-1.34) <.001
FEV1 to FVC ratio 1.35 (1.14-1.60) <.001 1.21 (1.00-1.46) .05
Men (n=1074)
% predicted FEV1 1.27 (1.17-1.39) <.001 1.20 (1.09-1.31) <.001
% predicted FVC 1.40 (1.25-1.56) <.001 1.28 (1.13-1.43) <.001
FEV1 to FVC ratio 1.27 (1.02-1.58) .04 1.16 (0.91-1.48) .24
Women (n=1051)
% predicted FEV1 1.23 (1.12-1.36) <.001 1.22 (1.11-1.35) <.001
% predicted FVC 1.25 (1.12-1.40) <.001 1.25 (1.12-1.40) <.001
FEV1 to FVC ratio 1.42 (1.08-1.85) .01 1.32 (1.00-1.74) .05
White (n=1324)
% predicted FEV1 1.27 (1.16-1.38) <.001 1.23 (1.12-1.35) <.001
% predicted FVC 1.37 (1.23-1.53) <.001 1.29 (1.15-1.45) <.001
FEV1 to FVC ratio 1.38 (1.09-1.75) .008 1.27 (0.99-1.64) .06
Black (n=801)
% predicted FEV1 1.26 (1.15-1.38) <.001 1.17 (1.07-1.29) .001
% predicted FVC 1.31 (1.18-1.46) <.001 1.21 (1.08-1.35) .001
FEV1 to FVC ratio 1.33 (1.05-1.69) .02 1.15 (0.88-1.49) .31
Heart failure with reduced ejection fraction (n=96)
% predicted FEV1 1.23 (1.12-1.37) <.001 1.16 (1.05-1.29) .006
% predicted FVC 1.26 (1.11-1.43) <.001 1.17 (1.03-1.33) .01
FEV1 to FVC ratio 1.49 (1.15-1.93) .002 1.31 (0.98-1.75) .065
Heart failure with preserved ejection fraction (n=91)
% predicted FEV1 1.22 (1.10-1.35) <.001 1.18 (1.05-1.32) .004
% predicted FVC 1.34 (1.18-1.52) <.001 1.25 (1.10-1.43) .001
FEV1 to FVC ratio 0.95 (0.69-1.29) .73 0.90 (0.65-1.26) .55
*
Adjusted for body mass index, previously identified predictors of heart failure in the Health ABC Study (age, history of coronary artery disease,
smoking status, systolic blood pressure, heart rate, left ventricular hypertrophy by electrocardiography, and creatinine, fasting glucose, and albumin
levels) and incident coronary heart disease.
†
Hazard ratios refer to 10% percent decrease of the parameter.
CI= confidence interval; HR=hazard ratio; FEV1=forced expiratory volume in 1st sec; FVC=forced vital capacity
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